Christopher Kenney
Direttore Tecnico/Scientifico/R&S presso XENON PHARMACEUTICALS INC.
Patrimonio netto: - $ in data 30/06/2024
Profilo
Christopher Kenney is currently the Chief Medical Officer at Xenon Pharmaceuticals, Inc. He previously held positions as the Senior Vice President-Medical Affairs at Acorda Therapeutics, Inc. from 2018 to 2019, the Chief Medical Officer at Cadent Therapeutics, Inc. from 2019 to 2020, and the Senior Vice President-Clinical Development at Biotie Therapies LLC from 2013 to 2016.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
| 05/04/2024 | 0 ( -.--% ) | - $ | 30/06/2024 |
Posizioni attive di Christopher Kenney
| Società | Posizione | Inizio |
|---|---|---|
| XENON PHARMACEUTICALS INC. | Direttore Tecnico/Scientifico/R&S | 23/08/2021 |
Precedenti posizioni note di Christopher Kenney
| Società | Posizione | Fine |
|---|---|---|
Cadent Therapeutics, Inc.
 Cadent Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Cadent Therapeutics, Inc. develops novel small molecule therapeutics to treat schizophrenia and other cognitive disorders. It focuses on modulating synaptic plasticity, the mechanism through which the brain builds and evolves the synaptic networks that carry out cognitive functions such as learning and memory. The company was founded by Kollol Pal, Frank S. Menniti, and Bertrand Leo Chenard in 2010 and is headquartered in Cambridge, MA. | Direttore Tecnico/Scientifico/R&S | 01/12/2020 |
| ACORDA THERAPEUTICS, INC. | Direttore Tecnico/Scientifico/R&S | 01/01/2019 |
| Biotie Therapies, Inc. | Direttore Tecnico/Scientifico/R&S | 01/01/2016 |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| ACORDA THERAPEUTICS, INC. | Health Technology |
| XENON PHARMACEUTICALS INC. | Health Technology |
| Aziende private | 2 |
|---|---|
Cadent Therapeutics, Inc.
Cadent Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Cadent Therapeutics, Inc. develops novel small molecule therapeutics to treat schizophrenia and other cognitive disorders. It focuses on modulating synaptic plasticity, the mechanism through which the brain builds and evolves the synaptic networks that carry out cognitive functions such as learning and memory. The company was founded by Kollol Pal, Frank S. Menniti, and Bertrand Leo Chenard in 2010 and is headquartered in Cambridge, MA. | Health Technology |
| Biotie Therapies, Inc. |
- Borsa valori
- Insiders
- Christopher Kenney
